RNA Targeting Small Molecule Drug Discovery Market - Global Forecast, 2021-2031F | 22.13% CAGR to Propel Market to USD 6.47 Billion as Pharma Partnerships Accelerate

Strategic partnerships, splicing modulators and non-coding RNA targets offer high-potential routes into oncology, rare disease and CNS therapies

Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "RNA Targeting Small Molecule Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's offering.

The Global RNA Targeting Small Molecule Drug Discovery Market is projected to grow from USD 1.95 Billion in 2025 to USD 6.47 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 22.13%. Market growth is being supported by rising demand for innovative treatments capable of addressing disease mechanisms that have historically been difficult to Target with conventional drug discovery methods.

RNA-targeting small molecules are designed to bind directly to complex RNA structures, including bulges, loops, and pseudoknots, to influence biological activity. Compared with other RNA-based therapeutic approaches, these compounds may offer advantages such as oral bioavailability, improved tissue distribution, and the potential to penetrate the blood-brain barrier. These characteristics are expanding their potential use in oncology, neurological diseases, infectious diseases, metabolic disorders, and rare genetic conditions.

Market Drivers: Strategic pharmaceutical partnerships and venture capital investment are major drivers of the Global RNA Targeting Small Molecule Drug Discovery Market. Pharmaceutical and biotechnology companies are seeking to diversify their research pipelines beyond traditional protein targets by gaining access to proprietary platforms that can modulate RNA function.

Industry collaborations are helping accelerate Target identification, candidate development, and clinical translation. In April 2025, Wayfinder Biosciences entered into a collaboration with Daiichi Sankyo to apply its RNA-targeting small molecule platform to neurodegenerative diseases. The agreement reflects growing reliance on external innovation and specialized discovery technologies.

The increasing global burden of cancer, neurological conditions, and rare genetic disorders is also strengthening demand for therapies that act on previously inaccessible biological targets. Continued advances in RNA biology, computational screening, structural analysis, and medicinal chemistry are improving the ability of developers to identify selective compounds and optimize promising candidates.

Market Challenges: Achieving sufficient selectivity remains a significant obstacle because RNA is structurally flexible and electrostatically complex. Candidate compounds may interact with abundant cellular RNAs, including ribosomes, increasing the risk of off- Target toxicity. Developers must therefore conduct extensive validation and safety studies, which can raise development costs, extend timelines, and contribute to higher preclinical attrition rates.

These technical risks also affect investment in emerging RNA drug discovery companies. According to the American Society of Gene & Cell Therapy, start-up financings across the gene, cell, and RNA therapy sector totaled $197 million in the second quarter of 2025, continuing a decline in deal volume and value over the preceding three quarters. Limited access to capital may restrict the progression of viable candidates from discovery into clinical development.

Market Trends: Small molecule splicing modulators are gaining attention for their potential to correct pre-mRNA processing defects associated with genetic diseases. By influencing exon inclusion or exclusion, these compounds may restore functional protein production and provide an alternative to more complex therapeutic approaches.

Clinical progress is reinforcing confidence in this modality. In September 2025, Skyhawk Therapeutics reported positive interim Phase 1 results for SKY-0515, including a 62% reduction in mutant huntingtin protein among patients with Huntington's disease. The findings demonstrated the potential of RNA-targeting small molecules to engage challenging central nervous system targets.

Research into Non-Coding RNA targets is also expanding the addressable market beyond protein-coding genes. Developers are increasingly investigating long non-coding RNAs involved in cellular regulation and disease progression, particularly in fibrosis, cardiovascular disease, and oncology. In May 2025, HAYA Therapeutics secured $65 million in Series A financing to advance HTX-001, its lead lncRNA-targeting candidate for heart failure, toward clinical trials.

Key Market Players:

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• Astrazeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F. Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

Report Scope: The report evaluates the Global RNA Targeting Small Molecule Drug Discovery Market by indication, end user, and region while examining the principal factors influencing industry growth.

RNA Targeting Small Molecule Drug Discovery Market, by Indication:

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Others

RNA Targeting Small Molecule Drug Discovery Market, by End Users:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Key Attributes:

For more information about this report visit https://www.researchandmarkets.com/r/b9b9c

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900